RANK, RANKL and osteoprotegerin in bone biology and disease. - Wikidata - wikimedia - TriplyDB

RANK, RANKL and osteoprotegerin in bone biology and disease.

RANK, RANKL and osteoprotegerin in bone biology and disease.

http://www.wikidata.org/entity/Q37199218

about

A comprehensive manually curated reaction map of RANKL/RANK-signaling pathway Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease Osteoprotegerin rich tumor microenvironment: implications in breast cancer Structure-based development of a receptor activator of nuclear factor- B ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis Tissue distribution of emulsified γ-tocotrienol and its long-term biological effects after subcutaneous administration.Trabecular bone volume and osteoprotegerin expression in uremic rats given high calcium.Immune activation, immunosenescence, and osteoprotegerin as markers of endothelial dysfunction in subclinical HIV-associated atherosclerosis.Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer.Osteoporosis: New-Generation Drugs.Relationship between Biochemical Bone Markers and Bone Mineral Density in Patients with Phenylketonuria under Restricted Diet.Osteoprotegerin in Cardiometabolic Disorders.Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients.Higher Levels of Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and Endovascular Damage in HIV-Suppressed Patients.Do epigenetic marks govern bone mass and homeostasis?Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis.Ac45 silencing mediated by AAV-sh-Ac45-RNAi prevents both bone loss and inflammation caused by periodontitis.Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?Current and emerging therapies for the treatment of osteoporosis Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin.Inhibitory effects of osteoprotegerin on osteoclast formation and function under serum-free conditions.Reciprocal cross-talk between Prostaglandin E2 and bone in prostate cancer: a current review.Can bisphosphonates play a role in the treatment of children with chronic kidney disease?Osteopontin and wound healing in bone.Denosumab--a powerful RANKL inhibitor to stop lytic metastases and other bone loss actions by osteoclasts.Biomarkers of bone turnover in oncology: applications in diagnosis and treatment.Phytoestrogens and bone health at different reproductive stages.Osteoimmunology: the expanding role of immunoreceptors in osteoclasts and bone remodeling Osteoprotegerin and kidney disease.Mechanisms of "kidney governing bones" theory in traditional Chinese medicine.The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Pathogenesis of Metastatic Calcification and Acute Pancreatitis in Adult T-Cell Leukemia under Hypercalcemic State.PTH(1-34)-induced changes in RANKL and OPG expression by human PDL cells modify osteoclast biology in a co-culture model with RAW 264.7 cells.Urinary osteoprotegerin: a potential biomarker of lupus nephritis disease activity.Effect of OPG gene mutation on protein expression and biological activity in osteoporosis.Osteoprotegerin exposure at different stages of osteoclastogenesis differentially affects osteoclast formation and function.Salvianolic acid B and danshensu induce osteogenic differentiation of rat bone marrow stromal stem cells by upregulating the nitric oxide pathway.Hypertension may affect tooth-supporting alveolar bone quality: a study in rats.Effects of estrogen deficiency and/or caffeine intake on alveolar bone loss, density, and healing: a study in rats.Diet and Exercise: a Match Made in Bone.The Effect of RANKL/OPG Balance on Reducing Implant Complications.

P2860

Q24599024-B87B5346-5E48-40B9-8781-EDB51E8803C8 Q26747224-AC489054-FF21-4800-BABC-F8AA28C425AC Q26748804-6DAE7342-3DA1-4F38-9226-07FC00EE137F Q27665673-31E5E029-0C4F-4944-B45E-8AD83320713D Q33694018-A82CF4F4-68C6-4EB2-9901-CE69BD11F29C Q34118018-16FAA7F7-1194-45E9-A669-9FF7BF9D8FAA Q34412603-4053776A-51CF-471C-822F-B938D00E5286 Q35048224-43AD1C2E-5CA3-4BF3-AF2B-5FC85427221B Q35095553-58DA72DB-8F9D-48E3-99D8-822B0960B967 Q35177301-AEA7EDA8-35E9-4C77-AF4C-20790951B13E Q35640787-105A26D9-FBC0-4B70-85E6-249FA10D70E7 Q35840828-73BE4C72-3B68-4329-AFEF-D2D01DE58151 Q35935297-4B613FB9-1D8E-48D0-9EA9-4FEBC1E6C663 Q36055881-1937E888-037D-4C18-912E-8FA4BDE1DE62 Q36134061-06241939-E448-449A-BCFC-6C8ED9F4060E Q36207488-96B43221-5E86-42CE-B5B8-B5EA0DDB318C Q36410243-14EB415C-5338-4981-9B39-71EC96A31EDD Q36890431-98791C56-C4DF-4A4D-90CE-160E6DDF46DD Q37408169-077D1239-12D7-4E90-A5A3-16F0620D502C Q37453332-579BEE8F-1DAC-4901-B1DB-00F7EA90C018 Q37579078-9FBF32C6-0033-410A-966D-BDD2580B4A38 Q37832414-CFA696CC-68F4-4F27-8DB3-F7BC7E01D00C Q37876085-10EACA55-4119-4D68-B47B-A2E7DDAFB34B Q38010350-0AE1E4E4-772F-4D5C-9E30-01977414E758 Q38088714-6EAA0DC6-DCC9-42B3-91F1-08FE923071F4 Q38112453-F98AFA10-00FE-4FCA-98A0-5F5563B0A227 Q38116019-7170A93C-183C-44C4-B30A-061B2E395929 Q38206487-C8818A0B-B127-432A-B4BA-92D44C25B900 Q38247462-C149D4DD-5FAE-4D28-B350-A88464B8D0B8 Q38851505-8AAAC658-C516-43C0-AEBF-F794D1932F79 Q39445928-70553DE3-D5D0-4604-8DA2-F93048CFBA06 Q39669177-3AAC1453-7E77-4D20-8AF7-EF5E662FC92B Q39952011-AC0F9CC5-6A63-4B76-8DBF-AC6551716B46 Q41116031-D679EEEB-440F-44D6-87D9-A498CBE128CB Q41184194-905E7B95-10D5-4CD4-9FFB-15EAAA37D076 Q42364665-E8A05FBB-2348-4B70-9715-C53B46B76A00 Q43115863-92AA5154-0673-4D06-9B8B-CF4F838C4EC7 Q44960686-0DFC1DEA-3541-4609-88DD-97E254F11F9F Q47114199-91FD5FED-939D-42EC-ABB1-85EFF2799DB0 Q47167957-94466ECF-8110-4186-A3C0-2B9B975A84D6

P2860

RANK, RANKL and osteoprotegerin in bone biology and disease.

http://www.wikidata.org/entity/Q37199218

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

RANK, RANKL and osteoprotegerin in bone biology and disease.

@en

RANK, RANKL and osteoprotegerin in bone biology and disease.

@nl

type

label

RANK, RANKL and osteoprotegerin in bone biology and disease.

@en

RANK, RANKL and osteoprotegerin in bone biology and disease.

@nl

prefLabel

RANK, RANKL and osteoprotegerin in bone biology and disease.

@en

RANK, RANKL and osteoprotegerin in bone biology and disease.

@nl

P1433

Q37199218-FE442C09-D4A8-4635-9646-69D00F4B65D7

P1476

Q37199218-E7A359BD-1DAF-475F-A8F6-30061E435720

P2093

Q37199218-641B06AC-0A72-4E65-8C64-E0CA730B7D1C

Q37199218-99F3A3F7-7D58-4CF6-8B34-59401CCD67A5

Q37199218-BB661BFC-DEA1-4E64-8DA0-EDD833C8038B

P2860

Q37199218-0895CF7C-BD04-4204-B586-57E29981BD98

Q37199218-11D07834-EA25-4AD8-88EA-5BB1A810760E

Q37199218-140FEB69-A27A-47FF-BB63-D282F5B97EFC

Q37199218-1FD0BFED-4633-4A1B-957D-261CFE7CA086

Q37199218-21BEF8BF-1A97-4217-9661-5F93A9F848DA

Q37199218-240121F4-3CFF-4AB4-814D-14AB21FBC65F

Q37199218-241DC59F-08BF-4E5C-809D-2CA62D49BECB

Q37199218-259AB062-396A-4D5E-8D15-1D23A039365F

Q37199218-27D5284D-69E3-45CE-A131-4C55E5ECB128

Q37199218-2D44CF05-DF36-4C8E-A6E0-5BBC3333317F

P2888

Q37199218-52A871B4-FCDE-4FA6-ADAA-63E6D26F4E5F

P304

Q37199218-66B63757-1213-444C-93CE-49DD7ACD41ED

P31

Q37199218-D937FF02-0B65-4927-A0A7-B1988C294CA0

P356

Q37199218-156A521C-F273-46E8-AF8E-03027D02CE51

P433

Q37199218-22B3D8F1-735D-4A59-903D-42B1F12A9430

P478

Q37199218-9464DA5A-6DBE-46D7-A696-B70F5520A6C5

P50

Q37199218-E45AA65F-70B1-46CD-9F66-8A23EA1034CB

P577

Q37199218-242DFBA1-0A83-4ECC-B1A9-F9C5511C7C7A

P5875

Q37199218-EE3BE1FE-7E2B-41AC-81A0-DD243DAEEA52

P698

Q37199218-ED4A4D71-0056-47F8-9A85-80FF2DDBAB4C

P932

Q37199218-8CE210EA-A4D7-4F83-B973-7C0F5101A876

P356

S12178-009-9046-7

P1433

Current reviews in musculoskeletal medicine

P1476

RANK, RANKL and osteoprotegerin in bone biology and disease

@en

P2093

H L Wright

http://www.w3.org/2001/XMLSchema#string

J Middleton

http://www.w3.org/2001/XMLSchema#string

M J Marshall

http://www.w3.org/2001/XMLSchema#string

P2860

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

RANK is essential for osteoclast and lymph node development

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity

Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis

The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development

RANKL-RANK signaling in osteoclastogenesis and bone disease

P2888

s12178-009-9046-7

P304

56-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12178-009-9046-7

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26240437

http://www.w3.org/2001/XMLSchema#string

P698

19468919

http://www.w3.org/2001/XMLSchema#string

P932

2684955

http://www.w3.org/2001/XMLSchema#string